Animal models have been key for disease mechanism research for years, but ethical concerns partly fuelled by the realisation that not all diseases can be recapitulated in animal systems have led to regulatory changes that are driving a shift towards animal-free alternatives. As regulations continue to evolve, the transition to animal-free models is becoming increasingly crucial for laboratories aiming to comply with new standards without compromising on scientific progress. The past decade has seen a boost in the development of animal-free three-dimensional models including explants, co-cultures, spheroids, organoids, and organ-on-chip systems, creating a varied landscape that has significantly transformed disease research. These models incorporate advancements in stem cell technology, bioengineering, and microfluidics to provide more physiologically relevant systems that bridge the gap between traditional two-dimensional cell culture and in-vivo studies. Whilst traditional two-dimensional cultures offer a cost-effective method with replicable results, they fail to accurately represent the natural structure of tissues and cell-cell interactions. By contrast, animal-free culture systems provide a more appropriate representation of human physiology and tissue architecture with relevance to in-vivo conditions. Therefore, these models enable more translatable research outcomes and have the potential to provide data for the reduction of the high failure rates currently marring clinical trials. This review explores the evolution, advantages, and applications of animal-free models in advancing human disease research and refining preclinical studies with an emphasis on cancer research.
{"title":"The Evolution and Application of Animal-Free Models in Drug Discovery and Disease Mechanism Research.","authors":"Eve Jarman, Cristina Tufarelli, Karen Brown","doi":"10.1093/mutage/geag003","DOIUrl":"https://doi.org/10.1093/mutage/geag003","url":null,"abstract":"<p><p>Animal models have been key for disease mechanism research for years, but ethical concerns partly fuelled by the realisation that not all diseases can be recapitulated in animal systems have led to regulatory changes that are driving a shift towards animal-free alternatives. As regulations continue to evolve, the transition to animal-free models is becoming increasingly crucial for laboratories aiming to comply with new standards without compromising on scientific progress. The past decade has seen a boost in the development of animal-free three-dimensional models including explants, co-cultures, spheroids, organoids, and organ-on-chip systems, creating a varied landscape that has significantly transformed disease research. These models incorporate advancements in stem cell technology, bioengineering, and microfluidics to provide more physiologically relevant systems that bridge the gap between traditional two-dimensional cell culture and in-vivo studies. Whilst traditional two-dimensional cultures offer a cost-effective method with replicable results, they fail to accurately represent the natural structure of tissues and cell-cell interactions. By contrast, animal-free culture systems provide a more appropriate representation of human physiology and tissue architecture with relevance to in-vivo conditions. Therefore, these models enable more translatable research outcomes and have the potential to provide data for the reduction of the high failure rates currently marring clinical trials. This review explores the evolution, advantages, and applications of animal-free models in advancing human disease research and refining preclinical studies with an emphasis on cancer research.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Innovating and further Validating the Buccal Micronucleus Cytome assay.","authors":"Emanuela Volpi, Michael Fenech","doi":"10.1093/mutage/geag006","DOIUrl":"https://doi.org/10.1093/mutage/geag006","url":null,"abstract":"","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In March 2024, a food poisoning incident in Japan was traced to red yeast rice (beni-koji) supplements contaminated with puberulic acid (PA), a mycotoxin produced by Penicillium adametzioides. Although PA was implicated in renal dysfunction in both humans and rats, its mutagenic potential had not been clarified. Here, we comprehensively assessed the mutagenicity of PA using a tiered approach that combined in silico, in vitro, and in vivo methods. In silico quantitative structure-activity relationship (QSAR) analyses predicted PA to be mutagenic, and in vitro Ames tests confirmed the positive finding. In contrast, in vivo assays, including the transgenic rodent gene mutation assay in mice and the Pig-a assay in rats, demonstrated no induction of mutations in kidney, glandular stomach and blood cells, even at high exposure levels. Collectively, these findings indicate that PA is mutagenic in vitro bacterial tests, but not in mammalian in vivo systems, suggesting that the overall concern for mutagenicity in humans is low.
{"title":"Assessment of mutagenic potential of puberulic acid contaminated in red yeast rice (beni-koji) health food supplements.","authors":"Kei-Ichi Sugiyama, Ayako Furuhama, Katsuyoshi Horibata, Masataka Tsuda, Kazuki Izawa, Genichiro Tsuji, Yosuke Demizu, Kohei Matsushita, Takeshi Toyoda, Yoko Hirabayashi, Yoshiro Saito, Masamitsu Honma","doi":"10.1093/mutage/geag005","DOIUrl":"https://doi.org/10.1093/mutage/geag005","url":null,"abstract":"<p><p>In March 2024, a food poisoning incident in Japan was traced to red yeast rice (beni-koji) supplements contaminated with puberulic acid (PA), a mycotoxin produced by Penicillium adametzioides. Although PA was implicated in renal dysfunction in both humans and rats, its mutagenic potential had not been clarified. Here, we comprehensively assessed the mutagenicity of PA using a tiered approach that combined in silico, in vitro, and in vivo methods. In silico quantitative structure-activity relationship (QSAR) analyses predicted PA to be mutagenic, and in vitro Ames tests confirmed the positive finding. In contrast, in vivo assays, including the transgenic rodent gene mutation assay in mice and the Pig-a assay in rats, demonstrated no induction of mutations in kidney, glandular stomach and blood cells, even at high exposure levels. Collectively, these findings indicate that PA is mutagenic in vitro bacterial tests, but not in mammalian in vivo systems, suggesting that the overall concern for mutagenicity in humans is low.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tetsuya Suzuki, Ann Hirota, Shigenori Iwai, Hiroyuki Kamiya
Base damage in DNA constitutes a major source of mutations, and consequently leads to cancers. In human cells, 8-oxo-7,8-dihydroguanine (8-hydroxyguanine) induces targeted G→T transversions, and untargeted base substitution mutations at positions distant from the damaged site (action-at-a-distance mutations). OGG1 is a base excision repair enzyme and suppresses the former mutations, but is involved in the latter mutations' process. In this study, 5-hydroxycytosine (CO), another oxidized base removed by base excision repair, was incorporated into the inside and outside regions of the supF gene, and the CO-plasmid DNAs were transfected into human U2OS cells. The damaged cytosine base caused base substitution mutations at the lesion site, and seemed to induce the action-at-a-distance mutations at a lower frequency than the oxidized guanine base. These results indicated that CO is mutagenic in human cells. In addition, the (6-4) photoproduct of 5'-TpT-3', the lesion repaired by another type of DNA repair pathway, nucleotide excision repair, did not cause the action-at-a-distance mutations.
{"title":"Mutagenicity of 5-hydroxycytosine in human cells.","authors":"Tetsuya Suzuki, Ann Hirota, Shigenori Iwai, Hiroyuki Kamiya","doi":"10.1093/mutage/geag004","DOIUrl":"https://doi.org/10.1093/mutage/geag004","url":null,"abstract":"<p><p>Base damage in DNA constitutes a major source of mutations, and consequently leads to cancers. In human cells, 8-oxo-7,8-dihydroguanine (8-hydroxyguanine) induces targeted G→T transversions, and untargeted base substitution mutations at positions distant from the damaged site (action-at-a-distance mutations). OGG1 is a base excision repair enzyme and suppresses the former mutations, but is involved in the latter mutations' process. In this study, 5-hydroxycytosine (CO), another oxidized base removed by base excision repair, was incorporated into the inside and outside regions of the supF gene, and the CO-plasmid DNAs were transfected into human U2OS cells. The damaged cytosine base caused base substitution mutations at the lesion site, and seemed to induce the action-at-a-distance mutations at a lower frequency than the oxidized guanine base. These results indicated that CO is mutagenic in human cells. In addition, the (6-4) photoproduct of 5'-TpT-3', the lesion repaired by another type of DNA repair pathway, nucleotide excision repair, did not cause the action-at-a-distance mutations.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Rita Guedes, Renato Cunha, Amélia M Silva, Isabel Gaivão
Colorectal cancer (CRC) remains a major health challenge due to its late-stage diagnosis and the variability in patient prognosis. This study explores the potential of DNA damage in peripheral blood lymphocytes (PBLs) as a biomarker for CRC, comparing it with standard clinical parameters. We assessed DNA strand breaks using the alkaline comet assay in 27 CRC patients at diagnosis and post-treatment, comparing these levels with 31 healthy controls. Patients received 5-fluorouracil (5-FU) -based chemotherapy (with irinotecan or oxaliplatin), radiotherapy, or combined chemoradiotherapy. At diagnosis (t0), DNA damage in PBLs was significantly higher in CRC compared to healthy controls (mean ± SD %DNA in tail: CRC 27.9 ± 14.0%; controls 6.5 ± 3.8%; p = 0.001), and independently of common confounding factors (sex, age, smoking, and alcohol consumption). Crucially, the prognostic signal came from baseline (t0): 6 of 27 patients relapsed/metastasised within 8-10 months, and high DNA damage basal levels was the only significant prognostic predictor (p = 0.0137), yielding an infinitely elevated Odds Ratio (95% CI: ≥2.203) and 100% sensitivity. In stark contrast, carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) showed limited performance. At t0, among patients with available serum data (n = 23), most values were below clinical cut-offs: CEA 3 ng/mL (14/23, 61%); CA19-9, 37 U/mL (19/23, 83%). Prognostic sensitivities were 50.0% (CEA) and 16.7% (CA19-9). Post-treatment (t1) increases in DNA damage are pharmacodynamically expected with DNA-damaging therapy. t1 values were higher in patients who relapsed (p < 0.001), whereas the within-patient change (Δ = t1 - t0) was not associated with outcome (p = 0.148); these post-treatment findings are exploratory. Evaluating DNA damage in PBLs, therefore, offers a valuable non-invasive biomarker for early detection, treatment monitoring, and short-term risk stratification in CRC, warranting validation in larger, stage-balanced cohorts.
{"title":"Evaluating DNA Damage in Peripheral Blood Lymphocytes: A Promising Biomarker for Diagnosis, Prognosis and Treatment Monitoring in Colorectal Cancer.","authors":"Ana Rita Guedes, Renato Cunha, Amélia M Silva, Isabel Gaivão","doi":"10.1093/mutage/geag001","DOIUrl":"https://doi.org/10.1093/mutage/geag001","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a major health challenge due to its late-stage diagnosis and the variability in patient prognosis. This study explores the potential of DNA damage in peripheral blood lymphocytes (PBLs) as a biomarker for CRC, comparing it with standard clinical parameters. We assessed DNA strand breaks using the alkaline comet assay in 27 CRC patients at diagnosis and post-treatment, comparing these levels with 31 healthy controls. Patients received 5-fluorouracil (5-FU) -based chemotherapy (with irinotecan or oxaliplatin), radiotherapy, or combined chemoradiotherapy. At diagnosis (t0), DNA damage in PBLs was significantly higher in CRC compared to healthy controls (mean ± SD %DNA in tail: CRC 27.9 ± 14.0%; controls 6.5 ± 3.8%; p = 0.001), and independently of common confounding factors (sex, age, smoking, and alcohol consumption). Crucially, the prognostic signal came from baseline (t0): 6 of 27 patients relapsed/metastasised within 8-10 months, and high DNA damage basal levels was the only significant prognostic predictor (p = 0.0137), yielding an infinitely elevated Odds Ratio (95% CI: ≥2.203) and 100% sensitivity. In stark contrast, carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) showed limited performance. At t0, among patients with available serum data (n = 23), most values were below clinical cut-offs: CEA 3 ng/mL (14/23, 61%); CA19-9, 37 U/mL (19/23, 83%). Prognostic sensitivities were 50.0% (CEA) and 16.7% (CA19-9). Post-treatment (t1) increases in DNA damage are pharmacodynamically expected with DNA-damaging therapy. t1 values were higher in patients who relapsed (p < 0.001), whereas the within-patient change (Δ = t1 - t0) was not associated with outcome (p = 0.148); these post-treatment findings are exploratory. Evaluating DNA damage in PBLs, therefore, offers a valuable non-invasive biomarker for early detection, treatment monitoring, and short-term risk stratification in CRC, warranting validation in larger, stage-balanced cohorts.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Page B McKinzie, Rutu R Valapil, Emily L Heil, James E Polli, Meagan B Myers, Mason G Pearce, Vasily N Dobrovolsky
Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public on-line repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 one to three years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.
{"title":"Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans.","authors":"Page B McKinzie, Rutu R Valapil, Emily L Heil, James E Polli, Meagan B Myers, Mason G Pearce, Vasily N Dobrovolsky","doi":"10.1093/mutage/geag002","DOIUrl":"https://doi.org/10.1093/mutage/geag002","url":null,"abstract":"<p><p>Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public on-line repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 one to three years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael J Burgum, Stephen J Evans, Ilaria Zanoni, Magda Blosi, Gareth J Jenkins, Shareen H Doak
Nanoparticle genotoxicity can be induced through several mechanisms, but there are currently no nanoparticle positive controls available for the evaluation of in vitro genotoxicity. Tungsten carbide-cobalt (WC/Co) has been proposed as one possible candidate. The aim of this study was therefore to investigate the genotoxic profile of WC/Co (Co 8% wt.) utilizing the cytokinesis-blocked micronucleus (CBMN) assay, the mammalian cell gene mutation test, and comet assay following a 24-hour exposure. This was conducted in human lymphoblast (TK6) and Chinese hamster lung fibroblast (V79-4) cells. No cytotoxicity was observed in the TK6 CBMN assay even when significant induction of micronuclei was observed at 100 μg/ml (2-fold over control). In contrast, V79-4 cells demonstrated no significant genotoxicity or cytotoxicity in the CBMN assay. In the gene mutation assay significant mutagenicity was observed in V79-4 cells at 100 μg/ml (2-fold over control). Cellular uptake of the WC/Co nanoparticles was not qualitatively detected in either cell type when investigated with transmission electron microscopy. No genotoxicity was observed in either cell type with the comet assay. The data generated indicates that WC/Co nanoparticles may be used as a positive particulate control in the CBMN assay when using TK6 cells only; whilst in the gene mutation assay it can be used as a positive control for V79-4 cells. However, its use as a particle positive control is only possible when applying the highest test concentration of 100 μg/ml.
{"title":"Tungsten carbide-cobalt can function as a particle positive control for genotoxicity in vitro in specific cell lines.","authors":"Michael J Burgum, Stephen J Evans, Ilaria Zanoni, Magda Blosi, Gareth J Jenkins, Shareen H Doak","doi":"10.1093/mutage/geaf021","DOIUrl":"10.1093/mutage/geaf021","url":null,"abstract":"<p><p>Nanoparticle genotoxicity can be induced through several mechanisms, but there are currently no nanoparticle positive controls available for the evaluation of in vitro genotoxicity. Tungsten carbide-cobalt (WC/Co) has been proposed as one possible candidate. The aim of this study was therefore to investigate the genotoxic profile of WC/Co (Co 8% wt.) utilizing the cytokinesis-blocked micronucleus (CBMN) assay, the mammalian cell gene mutation test, and comet assay following a 24-hour exposure. This was conducted in human lymphoblast (TK6) and Chinese hamster lung fibroblast (V79-4) cells. No cytotoxicity was observed in the TK6 CBMN assay even when significant induction of micronuclei was observed at 100 μg/ml (2-fold over control). In contrast, V79-4 cells demonstrated no significant genotoxicity or cytotoxicity in the CBMN assay. In the gene mutation assay significant mutagenicity was observed in V79-4 cells at 100 μg/ml (2-fold over control). Cellular uptake of the WC/Co nanoparticles was not qualitatively detected in either cell type when investigated with transmission electron microscopy. No genotoxicity was observed in either cell type with the comet assay. The data generated indicates that WC/Co nanoparticles may be used as a positive particulate control in the CBMN assay when using TK6 cells only; whilst in the gene mutation assay it can be used as a positive control for V79-4 cells. However, its use as a particle positive control is only possible when applying the highest test concentration of 100 μg/ml.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":"592-602"},"PeriodicalIF":4.3,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12720410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The standard comet assay detects DNA strand breaks and alkali-labile sites, but these lesions are nonspecific. They may result directly from genotoxic agents or arise as intermediates during the repair of other DNA damage, such as oxidized bases or bulky DNA adducts. Different approaches have been developed to generate or trap these repair intermediates, making them detectable with the comet assay. Recently, the combination of the comet assay with DNA repair inhibitors like hydroxyurea and cytosine arabinoside has been proposed to detect bulky DNA adducts. These lesions are mainly repaired through nucleotide excision repair, a process that transiently produces strand breaks when damaged oligonucleotides are excised. Normally, these intermediates are rapidly repaired by DNA resynthesis and ligation. However, by inhibiting this repair step, strand breaks persist and can be detected by the comet assay. This strategy has been applied in various fields, including genotoxicity testing, environmental toxicology, human biomonitoring, and studies on DNA repair kinetics. This review focuses specifically on the use of hydroxyurea, cytosine arabinoside, and aphidicolin in in vitro experiments to evaluate the utility and specificity of this method for detecting different types of DNA lesions. Notably, in ~70% of studies reviewed, the inclusion of DNA repair inhibitors led to a significant increase in DNA damage, highlighting the added value of this approach. However, although the method enhances sensitivity to bulky adducts, it also responds to other types of damage, such as those induced by alkylating or oxidative agents.
{"title":"The use of DNA repair inhibitors and the comet assay-an overview.","authors":"E Saenz-Martinez, A López de Cerain, A Azqueta","doi":"10.1093/mutage/geaf025","DOIUrl":"10.1093/mutage/geaf025","url":null,"abstract":"<p><p>The standard comet assay detects DNA strand breaks and alkali-labile sites, but these lesions are nonspecific. They may result directly from genotoxic agents or arise as intermediates during the repair of other DNA damage, such as oxidized bases or bulky DNA adducts. Different approaches have been developed to generate or trap these repair intermediates, making them detectable with the comet assay. Recently, the combination of the comet assay with DNA repair inhibitors like hydroxyurea and cytosine arabinoside has been proposed to detect bulky DNA adducts. These lesions are mainly repaired through nucleotide excision repair, a process that transiently produces strand breaks when damaged oligonucleotides are excised. Normally, these intermediates are rapidly repaired by DNA resynthesis and ligation. However, by inhibiting this repair step, strand breaks persist and can be detected by the comet assay. This strategy has been applied in various fields, including genotoxicity testing, environmental toxicology, human biomonitoring, and studies on DNA repair kinetics. This review focuses specifically on the use of hydroxyurea, cytosine arabinoside, and aphidicolin in in vitro experiments to evaluate the utility and specificity of this method for detecting different types of DNA lesions. Notably, in ~70% of studies reviewed, the inclusion of DNA repair inhibitors led to a significant increase in DNA damage, highlighting the added value of this approach. However, although the method enhances sensitivity to bulky adducts, it also responds to other types of damage, such as those induced by alkylating or oxidative agents.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":"577-591"},"PeriodicalIF":4.3,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12720409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Microplastics are emerging pollutants of global concern, and their widespread presence poses a serious threat to aquatic and terrestrial ecosystems. The current study investigated the water quality and the presence of microplastics in water and native fish samples of the Karamana River, Kerala, India. The water quality was analyzed using various physicochemical parameters, including the dissolved oxygen, biochemical oxygen demand, and chemical oxygen demand. Microplastics isolated from water and native fish samples were characterized using Fourier transform infrared (FTIR) spectroscopy. DNA damage in fish liver and gill cells was assessed using the comet assay (single-cell gel electrophoresis). The water quality assessment revealed metals in the water within the acceptable limits, reduced dissolved oxygen, and increased biochemical oxygen demand and chemical oxygen demand, which indicate a river water ecosystem in hypoxic conditions, and the higher level of the most probable number index confirmed the presence of coliforms in this river. The microplastics isolated from the water and native fish samples were in fibers, fragments, film, pellets, and foams in nature. The abundance of microplastics in the river confirmed the load of microplastic pollution, which varied among the sites. FTIR spectroscopy analysis confirmed the presence of microplastic polymers such as polyethylene, polypropylene, polystyrene, polyamide, polyoxymethylene, and polyester in the water and native fish samples of the Karamana River. The increased percentage of tail DNA in the liver and gill cells of the fish inhabitants of the Karamana River, compared with the control fish, indicated DNA damage; this could be due to the microplastics in that aquatic ecosystem.
{"title":"Water quality assessment and genotoxicity in fishes of Karamana River, Kerala, India: an insight of microplastic pollution.","authors":"Ammu Ulakesan, Shilpa Latha Sunil, Reshma Ramarajan, Shanthala Mallikarjunaiah, Hunasanahally Puttaswamygowda Gurushankara","doi":"10.1093/mutage/geaf020","DOIUrl":"10.1093/mutage/geaf020","url":null,"abstract":"<p><p>Microplastics are emerging pollutants of global concern, and their widespread presence poses a serious threat to aquatic and terrestrial ecosystems. The current study investigated the water quality and the presence of microplastics in water and native fish samples of the Karamana River, Kerala, India. The water quality was analyzed using various physicochemical parameters, including the dissolved oxygen, biochemical oxygen demand, and chemical oxygen demand. Microplastics isolated from water and native fish samples were characterized using Fourier transform infrared (FTIR) spectroscopy. DNA damage in fish liver and gill cells was assessed using the comet assay (single-cell gel electrophoresis). The water quality assessment revealed metals in the water within the acceptable limits, reduced dissolved oxygen, and increased biochemical oxygen demand and chemical oxygen demand, which indicate a river water ecosystem in hypoxic conditions, and the higher level of the most probable number index confirmed the presence of coliforms in this river. The microplastics isolated from the water and native fish samples were in fibers, fragments, film, pellets, and foams in nature. The abundance of microplastics in the river confirmed the load of microplastic pollution, which varied among the sites. FTIR spectroscopy analysis confirmed the presence of microplastic polymers such as polyethylene, polypropylene, polystyrene, polyamide, polyoxymethylene, and polyester in the water and native fish samples of the Karamana River. The increased percentage of tail DNA in the liver and gill cells of the fish inhabitants of the Karamana River, compared with the control fish, indicated DNA damage; this could be due to the microplastics in that aquatic ecosystem.</p>","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":"603-612"},"PeriodicalIF":4.3,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: Re: Rather et al. Carcinogenic parasites: Insights into the epidemiology and possible mechanisms of cancer.","authors":"","doi":"10.1093/mutage/geaf022","DOIUrl":"10.1093/mutage/geaf022","url":null,"abstract":"","PeriodicalId":18889,"journal":{"name":"Mutagenesis","volume":" ","pages":"613"},"PeriodicalIF":4.3,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}